Tag:
Ben Venue Laboratories
Latest Headlines
Latest Headlines
J&J opens up Doxil rationing on 'limited' new supply
After months of restricting Doxil treatment to current patients, Johnson & Johnson has opened up its rationing program to new ones.
J&J looks for workaround to ease Doxil shortage
The idea is to allow its former contract manufacturer to formulate the cancer drug, and then send it elsewhere for filling and packaging.
FDA brings Sun's Doxil copy online to fix shortage
Fresh off its cobbled-together solution to a methotrexate shortage, the FDA says it's sewn up an alternate supply of the scarce cancer drug Doxil . The agency has approved a substitute for the...
Leukemia drug shortage averted for now, FDA says
Disaster averted, say federal health officials. HHS Secretary Kathleen Sebelius told Congress yesterday that new supplies of the critically scarce drug methotrexate would be released in the coming
Sanofi yanks drug batch on CMO contamination fears
Here's another ripple from the Ben Venue Laboratories splashdown. Sanofi's ( $SNY ) Genzyme unit has recalled a batch of its leukemia drug Fludara because of worries about its sterility. The 9,380
Ben Venue's idled plant triggers 'dire' leukemia-drug shortage
Ben Venue Laboratories has another black eye. We've heard a lot about the ongoing shortages of Johnson & Johnson's ( $JNJ ) cancer treatment Doxil , the supply of which is suffering from...
GAO: FDA needs more power to address drug shortages
Giving the FDA more power may be the only way to address manufacturing problems that are leading to steady increases in cancer and nutritional drug shortages, the Government Accountability Office
J&J to release new Doxil batches
Johnson & Johnson ( $JNJ ) is releasing new batches of Doxil , a cancer drug that has been in short supply recently as a result of problems at contract manufacturer Ben Venue Laboratories , a unit of
Doxil supplier's woes shine spotlight on CMO activity
Thanks to an ongoing shortage of Johnson & Johnson's ( $JNJ ) cancer drug Doxil , the unfolding drama at Ben Venue Laboratories has been on center stage. The FDA has repeatedly jumped on the
EMA pulls cancer meds made by troubled CMO
More bad news for customers of the contract manufacturer Ben Venue Laboratories : European authorities are recalling three cancer drugs made by the Boehringer Ingelheim unit and putting restrictions
